Cargando…

Metabolite profiling of guanfacine in plasma and urine of healthy Japanese subjects after oral administration of guanfacine extended‐release tablets

Guanfacine is used for the treatment of attention‐deficit/hyperactivity disorder (ADHD). Using liquid chromatography–tandem mass spectrometry (LC–MS/MS), metabolite profiling of guanfacine was performed in plasma and urine collected from healthy Japanese adults following repeated oral administration...

Descripción completa

Detalles Bibliográficos
Autores principales:	Inoue, Yuji, Morita, Hirotoshi, Nozawa, Kohei, Kanazu, Takushi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Original Papers
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6790749/ https://www.ncbi.nlm.nih.gov/pubmed/31313320 http://dx.doi.org/10.1002/bdd.2201

Ejemplares similares

Pharmacokinetics of Coadministration of Guanfacine Extended Release and Methylphenidate Extended Release
por: Roesch, Benno, et al.
Publicado: (2013)

Pharmacokinetics of Coadministered Guanfacine Extended Release and Lisdexamfetamine Dimesylate
por: Roesch, Benno, et al.
Publicado: (2013)

Clinical utility of guanfacine extended release in the treatment of ADHD in children and adolescents
por: Bello, Nicholas T
Publicado: (2015)

Guanfacine Extended Release: A New Pharmacological Treatment Option in Europe
por: Huss, Michael, et al.
Publicado: (2015)

Profile of guanfacine extended release and its potential in the treatment of attention-deficit hyperactivity disorder
por: Martinez-Raga, Jose, et al.
Publicado: (2015)

Chronic Administrations of Guanfacine on Mesocortical Catecholaminergic and Thalamocortical Glutamatergic Transmissions
por: Fukuyama, Kouji, et al.
Publicado: (2021)

Attention deficits following ADEM ameliorated by guanfacine
por: Singh-Curry, Victoria, et al.
Publicado: (2010)

Effect of Enteral Guanfacine on Dexmedetomidine Use in the ICU
por: Fetters, Megan B., et al.
Publicado: (2022)

Once-daily treatment of ADHD with guanfacine: patient implications
por: Strange, Brandon C
Publicado: (2008)

An in vitro evaluation of guanfacine as a substrate for P-glycoprotein
por: Gillis, Nancy K, et al.
Publicado: (2011)

T47. GUANFACINE AUGMENTATION OF ATTENTIONAL FUNCTIONING IN THE SCHIZOPHRENIA SPECTRUM
Publicado: (2020)

A Retrospective Analysis of Guanfacine for the Pharmacological Management of Delirium
por: Jiang, Shixie, et al.
Publicado: (2023)

Guanfacine extended release for children and adolescents with attention-deficit/hyperactivity disorder: efficacy following prior methylphenidate treatment
por: Huss, Michael, et al.
Publicado: (2016)

Delayed Signs and Symptoms of Extended Release Guanfacine Overdose in Two Adolescent Patients: Implications of Monitoring on the Psychiatry Unit
por: Mishra, Sanskriti, et al.
Publicado: (2022)

Guanfacine for the Treatment of Cognitive Disorders: A Century of Discoveries at Yale
por: Arnsten, Amy F.T., et al.
Publicado: (2012)

Stressing the potential of guanfacine as a treatment for cocaine use disorder
por: Lustberg, Daniel, et al.
Publicado: (2020)

Guanfacine as an effective drug for the treatment of tic disorder. Case report
por: Del Sol Calderon, P., et al.
Publicado: (2021)

Comparative efficacy and safety of attention-deficit/hyperactivity disorder pharmacotherapies, including guanfacine extended release: a mixed treatment comparison
por: Joseph, Alain, et al.
Publicado: (2017)

Guanfacine monotherapy for ADHD/ASD comorbid with Tourette syndrome: a case report
por: Okazaki, Kosuke, et al.
Publicado: (2019)

Psychostimulants Modafinil, Atomoxetine and Guanfacine Impair Bone Cell Differentiation and MSC Migration
por: Wagener, Nele, et al.
Publicado: (2022)

Noradrenergic Modulation of Learned and Innate Behaviors in Dopamine Transporter Knockout Rats by Guanfacine
por: Volnova, Anna, et al.
Publicado: (2023)

Does Guanfacine Extended Release Impact Functional Impairment in Children with Attention-Deficit/Hyperactivity Disorder? Results from a Randomized Controlled Trial
por: Stein, Mark A., et al.
Publicado: (2015)

Safety and efficacy of guanfacine extended-release in adults with attention-deficit/hyperactivity disorder: an open-label, long-term, phase 3 extension study
por: Iwanami, Akira, et al.
Publicado: (2020)

Efficacy and safety of guanfacine extended‐release in Japanese adults with attention‐deficit/hyperactivity disorder: Exploratory post hoc subgroup analyses of a randomized, double‐blind, placebo‐controlled study
por: Naya, Noriyuki, et al.
Publicado: (2020)

Cost Effectiveness of Guanfacine Extended Release as an Adjunctive Therapy to a Stimulant Compared with Stimulant Monotherapy for the Treatment of Attention-Deficit Hyperactivity Disorder in Children and Adolescents
por: Sikirica, Vanja, et al.
Publicado: (2012)

Correction to: Safety and efficacy of guanfacine extended-release in adults with attention-deficit/hyperactivity disorder: an open-label, long-term, phase 3 extension study
por: Iwanami, Akira, et al.
Publicado: (2020)

Noradrenergic Add-on Therapy with Extended-Release Guanfacine in Alzheimer’s Disease (NorAD): study protocol for a randomised clinical trial and COVID-19 amendments
por: Hoang, Karen, et al.
Publicado: (2022)

Effects of alpha 2-adrenoceptor agonists dexmedetomidine and guanfacine on morphine analgesia and tolerance in rats
por: Gursoy, Sinan, et al.
Publicado: (2011)

Successful use of guanfacine in a patient with chronic refractory cough: A case report
por: Kirschen, Gregory W., et al.
Publicado: (2017)

Guanfacine’s mechanism of action in treating prefrontal cortical disorders: Successful translation across species
por: Arnsten, Amy F.T.
Publicado: (2020)

Guanfacine inhibits interictal epileptiform events and sodium currents in prefrontal cortex pyramidal neurons
por: Pasierski, Michał, et al.
Publicado: (2023)

Successful Treatment of Tourette Syndrome With a Combination of Guanfacine and Aripiprazole: A Case Series
por: George, Tikku, et al.
Publicado: (2023)

Comparative Efficacy of Guanfacine Extended Release Versus Atomoxetine for the Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents: Applying Matching-Adjusted Indirect Comparison Methodology
por: Sikirica, Vanja, et al.
Publicado: (2013)

A retrospective medical chart review of clinical outcomes in children and adolescents with attention-deficit/hyperactivity disorder treated with guanfacine extended-release in routine Canadian clinical practice
por: van Stralen, Judy, et al.
Publicado: (2021)

Neurocognitive dysfunction and pharmacological intervention using guanfacine in a rhesus macaque model of self-injurious behavior
por: Freeman, Z T, et al.
Publicado: (2015)

Guanfacine treatment improves ADHD phenotypes of impulsivity and hyperactivity in a neurofibromatosis type 1 mouse model
por: Lukkes, J. L., et al.
Publicado: (2020)

Authors’ Reply to Alatorre et al.: “Cost Effectiveness of Guanfacine Extended-Release Versus Atomoxetine for the Treatment of Attention-Deficit/Hyperactivity Disorder: Application of a Matching-Adjusted Indirect Comparison”
por: Erder, M. Haim, et al.
Publicado: (2013)

Treatment Patterns, Health Care Resource Utilization, and Health Care Cost Associated with Atypical Antipsychotics or Guanfacine Extended Release in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder in Quebec, Canada
por: Lachaine, Jean, et al.
Publicado: (2019)

The behavioural response of mice lacking NK(1) receptors to guanfacine resembles its clinical profile in treatment of ADHD
por: Pillidge, Katharine, et al.
Publicado: (2014)

Randomised, double-blind, placebo-controlled crossover study of single-dose guanfacine in unilateral neglect following stroke
por: Dalmaijer, Edwin S, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_fs5b5mejlk2lliqqn3q2g5ddob